CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell exhaustion in chronic viral infection and cancers. Under some conditions, TIM-3 expression has also been shown to be stimulatory. Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), is being targeted for cancer immunotherapy, it is important to identify the circumstances under which TIM-3 can inhibit and activate T-cell responses. Here we show that TIM-3 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), another well-known molecule expressed on activated T cells and involved in T-cell inhibition. Biochemical, biophysical and X-ray crystallography studies show that the membrane-distal immunoglobulin-variable (IgV)-like amino-terminal domain of each is crucial to these interactions. The presence of CEACAM1 endows TIM-3 with inhibitory function. CEACAM1 facilitates the maturation and cell surface expression of TIM-3 by forming a heterodimeric interaction in cis through the highly related membrane-distal N-terminal domains of each molecule. CEACAM1 and TIM-3 also bind in trans through their N-terminal domains. Both cis and trans interactions between CEACAM1 and TIM-3 determine the tolerance-inducing function of TIM-3. In a mouse adoptive transfer colitis model, CEACAM1-deficient T cells are hyper-inflammatory with reduced cell surface expression of TIM-3 and regulatory cytokines, and this is restored by T-cell-specific CEACAM1 expression. During chronic viral infection and in a tumour environment, CEACAM1 and TIM-3 mark exhausted T cells. Co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumour immune responses with improved elimination of tumours in mouse colorectal cancer models. Thus, CEACAM1 serves as a heterophilic ligand for TIM-3 that is required for its ability to mediate T-cell inhibition, and this interaction has a crucial role in regulating autoimmunity and anti-tumour immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interaction between TIM-3 and its four ligands (galectin 9, high mobility group protein B1, phosphatidyl serine, and carcinoembryonic antigen cell adhesion molecule 1) can diminish anti-tumor immunity through a variety of mechanisms including inducing CD8+ T cell death and exhaustion (Huang et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Huang et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We stimulated primary microglia with galectin-9 and CEACAM1, both of which mediate TIM-3 function in T cells by phosphorylating Y256 and Y263 residues34,35. This treatment had no effect on pSMAD2 expression”
From Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease (2025) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · cited 2×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · cited 4×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
InfluentialHaploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Multiple Sequence Alignment Using ClustalW and ClustalX
Thompson, J. D., Gibson, T. J., & Higgins, D. G. (2003) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi0203s00 · Cited by 2,971 · cited 1×
“In addition, multiple sequencealignmentswereperformedusingClustalW 45 .”
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM
Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R., & Leslie, A. G. W. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910048675 · Cited by 2,860 · cited 2×
“ThedatawereprocessedwithMosflm 40 andthe CCP 4softwaresuite 41 .”
Direct observation of individual endogenous protein complexes in situ by proximity ligation
Söderberg, O., Gullberg, M., Jarvius, M., Ridderstråle, K., Leuchowius, K.-J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L.-G., et al. (2006) · Nature Methods · doi:10.1038/nmeth947 · Cited by 2,419
Cited by
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
“Recent studies showed that TIM-3 is co-expressed with and binds to CECAM1 and that this interaction is important in TIM-30s regulatory function (Huang et al., 2015).”
BackgroundFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
“Lag-3 structurally resembles the CD4 co-receptor and, indeed, binds to MHC class II with a higher affinity than CD4 (Figure 1A; Huard et al., 1995).”
BackgroundSelf-citationHallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
“CEACAM1 and phosphatidylserine have also been proposed as ligands for TIM-3 (refs 22,23).”
BackgroundImmune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
“TIM3 binding with antibody or ligand causes dissociation of Bat3, likely through the phosphorylation of Y265 and Y272, and reverses the inhibitory effects of Bat3 on TIM3 function.(85,93) It is therefore possible that while TIM3 itself might act as an inhibitory receptor, its association with Bat3 converts it to stimu…”
BackgroundCombination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145
“Huang and his colleague elucidated that TIM-3 and Ceacam-1 can form a heterodimer in both cis and trans which acts as a negative regulator of T cell responses [88].”
BackgroundThe future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
TIM3 comes of age as an inhibitory receptor
Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0224-6 · Cited by 959
Self-citationCoinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890
Tim‐3 and its role in regulating anti‐tumor immunity
Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856
Self-citationEnhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Kraehenbuehl, L., Weng, C.-H., Eghbali, S., Wolchok, J. D., & Merghoub, T. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00552-7 · Cited by 846
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 613
“25), which has been reported to be a partner of the T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and can be blocked therapeutically using antibodies to result in antitumor activity (26).”
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
“57,58 PD-1 interacts with Gal-9 can inhibit the progressed T cell death and promote CD8 + T cell expansion.”
BackgroundHuman NK cells: surface receptors, inhibitory checkpoints, and translational applications
Sivori, S., Vacca, P., Del Zotto, G., Munari, E., Mingari, M. C., & Moretta, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0206-4 · Cited by 555
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
Andrews, L. P., Yano, H., & Vignali, D. A. A. (2019) · Nature Immunology · doi:10.1038/s41590-019-0512-0 · Cited by 543
Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2524 · Cited by 523
“We also found that CEACAM1, a cell adhesion molecule shown to endow TIM3 with inhibitory function (49), was coexpressed with TIM3 to a much greater extent on TILs than infused T cells.”
BackgroundReversing T-cell Dysfunction and Exhaustion in Cancer
Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462
“Galectin-9 and CEACAM1 bind to Tim-3 to mediate T-cell inhibition (36, 37).”
BackgroundImmunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Multi-organ proteomic landscape of COVID-19 autopsies
Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q., Lu, T., Yue, L., Chen, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.004 · Cited by 408
Tim-3 finds its place in the cancer immunotherapy landscape
Acharya, N., Sabatos-Peyton, C., & Anderson, A. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000911 · Cited by 394
Self-citationTargeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Cai, L., Li, Y., Tan, J., Xu, L., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01499-1 · Cited by 391
“…expression, which increases HCC cell migration and invasion rates [46], (4) by autocrine signaling mediated through TIM-3 binding ligands, including Gal-9, thereby enabling these cells to avoid recognition and clearance by immune cells to sustain their survival and self-renewal [102–106].”
BackgroundDendritic cells as orchestrators of anticancer immunity and immunotherapy
Heras-Murillo, I., Adán-Barrientos, I., Galán, M., Wculek, S. K., & Sancho, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00859-1 · Cited by 383
“Expression of CEACAM1, another ligand that induces inhibitory signalling by TIM3, has been found to be upregulated in exhausted T cells in the TME 156 .”
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin, D. S., & Ribas, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.006 · Cited by 346
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Xu, J., Yin, T., & Lu, X.-J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 341
“In addition, Tim-3 directly binds to Galectin-9 and CEACAM1 to inhibit T cell function (38, 39).”
BackgroundDatar, I., Sanmamed, M. F., Wang, J., Henick, B. S., Choi, J., Badri, T., Dong, W., Mani, N., Toki, M., Mejías, L. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4142 · Cited by 326
“An immunosuppressive effect of TIM-3 signaling on T cells was reported to be related with the binding of Galectin-9 and CEACAM1 (25, 26).”
BackgroundLiu, B., Zhang, Y., Wang, D., Hu, X., & Zhang, Z. (2022) · Nature Cancer · doi:10.1038/s43018-022-00433-7 · Cited by 309
LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers
Pan, J.-H., Zhou, H., Cooper, L., Huang, J.-L., Zhu, S.-B., Zhao, X.-X., Ding, H., Pan, Y.-L., & Rong, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00006 · Cited by 300
“TIM-3, a crucial surface protein on exhausted T cells (38), is highly correlated with LAYN expression in COAD and STAD.”
BackgroundSingle-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression
Yeo, A. T., Rawal, S., Delcuze, B., Christofides, A., Atayde, A., Strauss, L., Balaj, L., Rogers, V. A., Uhlmann, E. J., Varma, H., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01215-0 · Cited by 290
NK cells and ILCs in tumor immunotherapy
Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., et al. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100870 · Cited by 270
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease
Attanasio, J., & Wherry, E. J. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.022 · Cited by 256
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation
Joller, N., Anderson, A. C., & Kuchroo, V. K. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.010 · Cited by 249
Self-citationInhibitory Receptors Beyond T Cell Exhaustion
Fuertes Marraco, S. A., Neubert, N. J., Verdeil, G., & Speiser, D. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00310 · Cited by 244
“It also impacts on the design of strategies to block iRs and reverse T cell function, as it might be more relevant to interfere with other interacting partners such as CEACAM-1 rather than blocking TIM3.”
BackgroundInfluentialTIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Du, W., Yang, M., Turner, A., Xu, C., Ferris, R., Huang, J., Kane, L., & Lu, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030645 · Cited by 242
“Ceacam-1 and TIM-3 are co-expressed, and the two molecules can form in trans a specific heterodimer which functions as a negative regulator of T cell responses [45].”
BackgroundImmune checkpoints in the tumor microenvironment
Toor, S. M., Sasidharan Nair, V., Decock, J., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.021 · Cited by 236
Immune determinants of the pre-metastatic niche
Patras, L., Shaashua, L., Matei, I., & Lyden, D. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.018 · Cited by 221
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
Schnell, A., Bod, L., Madi, A., & Kuchroo, V. K. (2020) · Cell Research · doi:10.1038/s41422-020-0277-x · Cited by 224
“Subsequently, several other ligands of TIM-3 have been identified, including phosphatidylserine and CEACAM1.(92,93) Administration of anti-TIM-3 antibodies in EAE results in enhanced clinical and pathological disease scores with an increased activation phenotype in macrophages.”
BackgroundSelf-citationLee, Y., Shin, J. H., Longmire, M., Wang, H., Kohrt, H. E., Chang, H. Y., & Sunwoo, J. B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2665 · Cited by 219
“Other Tim-3 ligands, such as HMGB1 (40) and Ceacam1 (41), have been identified and could potentially regulate Tim-3–mediated inhibition in SCCHN.”
BackgroundTIM-3: An update on immunotherapy
Zhao, L., Cheng, S., Fan, L., Zhang, B., & Xu, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107933 · Cited by 217
Killers 2.0: NK cell therapies at the forefront of cancer control
Hodgins, J. J., Khan, S. T., Park, M. M., Auer, R. C., & Ardolino, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129338 · Cited by 217
TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection
Jayaraman, P., Jacques, M. K., Zhu, C., Steblenko, K. M., Stowell, B. L., Madi, A., Anderson, A. C., Kuchroo, V. K., & Behar, S. M. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005490 · Cited by 209
Self-citationT cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 199
“Other ligands for TIM3 are carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) [132], HMGB1 [133] and phosphatidylserine [134].”
BackgroundTregs: Where We Are and What Comes Next?
Zhao, H., Liao, X., & Kang, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01578 · Cited by 196
“Besides galectin-9, phosphatidyl serine, high mobility group protein B1, carcinoembryonic antigen cell adhesion molecule-1 was identified as another novel cell surface ligand of Tim-3 recently (154).”
BackgroundBeyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
Le Mercier, I., Lines, J. L., & Noelle, R. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00418 · Cited by 195
“CEACAM-1 endows TIM-3-mediated inhibitory function by facilitating TIM-3 surface expression (44).”
BackgroundThe untold story of IFN-γ in cancer biology
Kursunel, M. A., & Esendagli, G. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.07.005 · Cited by 192
Modulation of regulatory T cell function and stability by co-inhibitory receptors
Lucca, L. E., & Dominguez-Villar, M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0296-3 · Cited by 189
Immune-inflammation gene signatures in endometriosis patients
Ahn, S. H., Khalaj, K., Young, S. L., Lessey, B. A., Koti, M., & Tayade, C. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.07.005 · Cited by 186
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
Pesce, S., Greppi, M., Grossi, F., Del Zotto, G., Moretta, L., Sivori, S., Genova, C., & Marcenaro, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01242 · Cited by 187
“TIM-3 is a checkpoint receptor that binds several ligands including galectin-9 (Gal-9) (48), phosphatidylserine on apoptotic cells (49), high mobility group box 1 (HMGB1) (50), and CEA-related cell adhesion molecule-1(CEACAM1) (51).”
BackgroundImmune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Cao, Y., Wang, X., Jin, T., Tian, Y., Dai, C., Widarma, C., Song, R., & Xu, F. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00348-8 · Cited by 180
Meng, L., Wu, H., Wu, J., Ding, P., He, J., Sang, M., & Liu, L. (2024) · Cell Death & Disease · doi:10.1038/s41419-023-06389-5 · Cited by 174
“The ligand CEACAM1 binding to TIM-3 plays a crucial role in regulating cell-mediated autoimmunity and anti-tumor immunity [100].”
BackgroundA comprehensive review of immune checkpoint inhibitors for cancer treatment
Arafat Hossain, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 178
Avery, L., Filderman, J., Szymczak-Workman, A. L., & Kane, L. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712107115 · Cited by 169
Wu, B., Shi, X., Jiang, M., & Liu, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01748-4 · Cited by 169
The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy
Kandel, S., Adhikary, P., Li, G., & Cheng, K. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.011 · Cited by 165
“Although the binding sites for Gal9 and CEACAM1 in the IgV domain are different, studies have shown that they induce the same downstream signaling events [23,29].”
BackgroundInfluentialTim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance
Tang, R., Rangachari, M., & Kuchroo, V. K. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101302 · Cited by 170
Self-citationEmerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 166
“Indeed, similar to targeted therapy, patients may eventually develop resistance to immunotherapy [32, 33] and some may even suffer hyperprogression after immunotherapy [34, 35].”
BackgroundInhibitory receptors as targets for cancer immunotherapy
Turnis, M. E., Andrews, L. P., & Vignali, D. A. A. (2015) · European Journal of Immunology · doi:10.1002/eji.201344413 · Cited by 152
Not All Immune Checkpoints Are Created Equal
De Sousa Linhares, A., Leitner, J., Grabmeier-Pfistershammer, K., & Steinberger, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01909 · Cited by 148
“The heterodimermodels have since been withdrawn and further work is required to establish an interaction between CEACAM-1 and TIM-3 (123).”
BackgroundMetabolic modulation of immune checkpoints and novel therapeutic strategies in cancer
Wang, Y., Wang, Y., Ren, Y., Zhang, Q., Yi, P., & Cheng, C. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.010 · Cited by 153
Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment
Xie, Q., Ding, J. P., & Chen, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.027 · Cited by 167
Novel targets for immune-checkpoint inhibition in cancer
Borgeaud, M., Sandoval, J. L., Obéid, M., Banna, G. L., Michielin, O. A., Addeo, A., & Friedlaender, A. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102614 · Cited by 158
Natural Killer Cells in Cancer Immunotherapy
Miller, J. S., & Lanier, L. L. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055653 · Cited by 137
“Cross-linking TIM3 with mAbs can suppress NK cell activation triggered by CD16, suggesting that it is an inhibitory receptor; however, TIM3 has no characteristic inhibitory signaling motifs in its cytoplasmic domain (Ndhlovu et al. 2012).”
BackgroundInfluentialHossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 154
“Furthermore, TIM‐3 forms a heterodimer in both cis and trans with another T‐cell inhibition molecule CEACAM1 (carcinoembryonic antigen cell adhesion molecule 1), which endows TIM‐3 with tolerance‐inducing functions.(202) The lessons learned from clinical studies indicated that upregulation of TIM‐3 and other immune ch…”
BackgroundTim-3 expression and its role in hepatocellular carcinoma
Liu, F., Liu, Y., & Chen, Z. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0667-4 · Cited by 134
“2C12) cc1 Anti-CEACAM1 Colorectal cancer [13]”
BackgroundInfluentialUnleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Ben‐Shmuel, A., Biber, G., & Barda‐Saad, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00275 · Cited by 146
“Since TIM-3 can bind additional ligands [such as phosphatidylserine and CEA-related cell adhesion molecule-1 (124, 125)], its activity, whether stimulatory or repressive, may be ligand dependent.”
BackgroundTIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
Sauer, N. J., Janicka, N., Szlasa, W., Skinderowicz, B., Kołodzińska, K., Dwernicka, W., Oślizło, M., Kulbacka, J., Novickij, V., & Karłowicz-Bodalska, K. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03516-1 · Cited by 157
“T cells lacking CEACAM1 are hyperinflammatory with reduced expression of cell surface TIM-3 and regulatory cytokines, but this effect is reversed when T cells specifically express CEACAM1 [97].”
BackgroundInfluentialJoller, N., & Kuchroo, V. K. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_62 · Cited by 133
“While Ceacam-1 and galectin-9 bind to different regions of the IgV domain of Tim-3, both ligands induce phosphorylation of the same two tyrosine residues required for functional activity of Tim-3 (Huang et al. 2015; Rangachari et al. 2012).”
BackgroundInfluentialSelf-citationLarimer, B. M., Bloch, E., Nesti, S., Austin, E. E., Wehrenberg-Klee, E. P., Boland, G. M., & Mahmood, U. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2407 · Cited by 133
“However, the role of TIM-3 in oncologic immunotherapy response has yet to be completely elucidated, as evidence supports its role in both immunogenic and tolerogenic pathways (9, 10).”
BackgroundInterferons and the immunogenic effects of cancer therapy
Minn, A. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.09.007 · Cited by 130
“As with PD-L1, blocking IDO and TIM-3 with small molecules and antibodies can improve anti-tumor activity [67,68], further demonstrating that ISGs can drive immune-mediated therapy resistance.”
BackgroundSources and Potential Photochemical Roles of Formaldehyde in an Urban Atmosphere in South China
Wang, C., Huang, X., Han, Y., Zhu, B., & He, L. (2017) · Journal of Geophysical Research Atmospheres · doi:10.1002/2017jd027266 · Cited by 135
Liu, J.-F., Wu, L., Yang, L.-L., Deng, W.-W., Mao, L., Wu, H., Zhang, W.-F., & Sun, Z.-J. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0713-7 · Cited by 125
Tsai, H.-F., & Hsu, P. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0341-0 · Cited by 145
“Most recently, CEACAM-1 was also identified as a novel cell surface ligand for Tim-3 [77].”
BackgroundCEACAM1 structure and function in immunity and its therapeutic implications
Kim, W. M., Huang, Y., Gandhi, A. K., & Blumberg, R. S. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101296 · Cited by 131
“More recently, T cell immunoglobulin and mucin-domain containing-3 (TIM-3) was identified as a ligand for CEACAM1 [15], representing the first non-CEACAM family, IgVcontaining host binding partner.”
BackgroundMethodInfluentialSelf-citationImmune checkpoint blockade opens a new way to cancer immunotherapy
Sadreddini, S., Baradaran, B., Aghebati‐Maleki, A., Sadreddini, S., Shanehbandi, D., Fotouhi, A., & Maleki, L. A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27816 · Cited by 132
“Tim‐3 contains extracellular Tgr domain, a transmembrane domain, a cytoplasmic tail, and a mucin domain (Huang et al., 2015).”
BackgroundCEACAM1 as a Multi-Purpose Target for Cancer Immunotherapy
Dankner, M., Gray‐Owen, S. D., Huang, Y., Blumberg, R. S., & Beauchemin, N. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1328336 · Cited by 132
“tolerance, exhibits biochemical interactions with CEACAM1, and serves as a CEACAM1 heterophilic ligand.(5,43) CEACAM1”
BackgroundInfluentialSelf-citationSabatos-Peyton, C. A., Nevin, J. T., Brock, A., Venable, J. D., Tan, D. J., Kassam, N., Xu, F., Taraszka, J. A., Wesemann, L. D., Pertel, T., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1385690 · Cited by 124
“CEACAM1 is predicted to bind within the vicinity of the CC’ and FG loops that frame the PtdSer binding cleft.(13)”
BackgroundSelf-citationClinical Insights Into Novel Immune Checkpoint Inhibitors
Lee, J. B., Ha, S.-J., & Kim, H. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.681320 · Cited by 112
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 124
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells
Kim, N., & Kim, H. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02041 · Cited by 120
“The cognate ligands for TIM-3 include galectin-9 (Gal9) (81), phosphatidylserine (PtdSer) on apoptotic cells (82), high mobility group box (HMGB)1 (83), and carcinoembryonic antigen-related cell adhesion molecule (CEACAM)-1 (5, 84).”
BackgroundTim-3 enhances FcεRI-proximal signaling to modulate mast cell activation
Phong, B. L., Avery, L., Sumpter, T. L., Gorman, J. V., Watkins, S. C., Colgan, J. D., & Kane, L. P. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150388 · Cited by 110
“Multiple cis- and trans-acting Tim-3 ligands have been described, and thus far include phosphatidylserine (PS), galectin-9, high mobility group protein B1 (HMGB1), and CEA CAM1, none of which is specific to Tim-3 (Han et al., 2013; Anderson, 2014; Gorman and Colgan, 2014; Huang et al., 2015).”
BackgroundInfluentialMechanisms of Drug Resistance in Melanoma
Winder, M. L., & Virós, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_17 · Cited by 127
Du, X., Wu, Z., Xu, Y., Liu, Y., Liu, W., Wang, T., Li, C., Zhang, C., Yi, F., Gao, L., et al. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0032-0 · Cited by 114
İmani, S., Farghadani, R., Roozitalab, G., Maghsoudloo, M., Emadi, M., Moradi, A., Abedi, B., & Kaboli, P. J. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03394-8 · Cited by 131
Natural Killer Cells: Tumor Surveillance and Signaling
Guzman, L. G. M., Keating, N., & Nicholson, S. E. (2020) · Cancers · doi:10.3390/cancers12040952 · Cited by 130
Jiang, X., Zhou, T., Xiao, Y., Yu, J., Dou, S., Chen, G., Wang, R., Xiao, H., Hou, C., Wang, W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1211219 · Cited by 103
Jie, H.-B., Srivastava, R. M., Argiris, A. E., Bauman, J. E., Kane, L., & Ferris, R. L. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0333 · Cited by 110
Co-stimulatory and co-inhibitory pathways in cancer immunotherapy
O’Neill, R., & Cao, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.003 · Cited by 110
Vito, C. D., Mikulak, J., Zaghi, E., Pesce, S., Marcenaro, E., & Mavilio, D. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.004 · Cited by 119
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
Zhang, C., & Liu, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01295 · Cited by 113
“binding of TIM-3 with its ligands, the tyrosine residues recruit certain signaling components that transduce inhibitory signaling, thereby promoting the inhibition, anergy, or exhaustion of immune cells (51, 73).”
BackgroundNovel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 114
“Furthermore, CEACAM-1 interacts with Tim-3 through its N-terminal structural domain to form heterodimers in cis and trans to promote Tim-3 maturation and expression on the surface of effector T cells, thereby inducing the generation of immune tolerance [215].”
BackgroundZhang, Y., Cai, P., Liang, T., Wang, L., & Hu, L. (2017) · Oncotarget · doi:10.18632/oncotarget.15954 · Cited by 98
“Moreover, TIM-3 blockade was associated with enhanced IFN-γ production, which indicated restoration of T cell function [23].”
BackgroundThe evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review
Mazzarella, L., Duso, B. A., Trapani, D., Belli, C., D’Amico, P., Ferraro, E., Viale, G., & Curigliano, G. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.035 · Cited by 105
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
Torphy, R., Schulick, R., & Zhu, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122642 · Cited by 97
“This treatment was also associated with increased T cell activation [70].”
BackgroundCellular and molecular mechanisms of CD8(+) T cell differentiation, dysfunction and exhaustion
Verdon, D. J., Mulazzani, M., & Jenkins, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197357 · Cited by 98
“It is co-expressed with TIM-3 on CD8+ exhausted/dysfunctional T cells, and they can bind both in cis and trans, leading to induction of tolerance and inhibiting anti-tumor function [202].”
BackgroundHarnessing NK Cells for Cancer Treatment
Minetto, P., Guolo, F., Pesce, S., Greppi, M., Obino, V., Ferretti, E., Sivori, S., Genova, C., Lemoli, R. M., & Marcenaro, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02836 · Cited by 104
“TIM-3 is a checkpoint receptor that binds several ligands including galectin-9 (Gal-9) (55), phosphatidylserine on apoptotic cells (56), high mobility group box 1 (56), and CEA-related cell adhesion molecule-1 (57).”
BackgroundNegative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 99
“This dual-blockade improved elimination of CT26 tumours (Huang et al., 2015).”
BackgroundInfluentialCurrent modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Lohmueller, J. J., & Finn, O. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.008 · Cited by 101
“This receptor is up-regulated on exhausted T cells and has been shown to suppress T cell functions and induce apoptosis (Huang et al., 2015; Sabatos et al., 2003; Zhu et al., 2005).”
Background
Metadata
- Authors
- Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., Clayton, K. L., Raab, M., Chen, Q., Beauchemin, N., Yazaki, P. J., Pyzik, M., Ostrowski, M. A., Glickman, J. N., Rudd, C. E., Ploegh, H. L., Franke, A., Petsko, G. A., Kuchroo, V. K., & Blumberg, R. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Brandeis University (US)
- Massachusetts Institute of Technology (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Oslo University Hospital (NO)
- University of Toronto (CA)
- University of Cambridge (GB)
- Sichuan University (CN)
- McGill University (CA)
- City Of Hope National Medical Center (US)
- St. Michael's Hospital (CA)
- Corresponding author
- Blumberg, Richard S.
- ORCID
- Venue
- Nature
- Published
- 2014-10-26
- Volume
- 517
- Issue
- 7534
- Pages
- 386-390
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4297519
- OpenAlex
- W2122730216
- Cited by
- 717
- References
- 58
- Citations by year
- 2026: 44 · 2025: 72 · 2024: 85 · 2023: 82 · 2022: 71 · 2021: 82 · 2020: 76 · 2019: 51 · 2018: 47 · 2017: 40 · 2016: 38 · 2015: 28
- FWCI
- 17.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR001102)
- National Institute of General Medical Sciences (R01GM032415, T32GM007122, GM-32415, R37GM032415, P41GM111244, R01GM026788)
- National Institute of Allergy and Infectious Diseases (AI 056299, P01AI073748, AI039671, AI073748, P01AI056299, P01AI039671)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK044319, DK0034854, R01DK053056, DK088199, DK053056, R56DK053056, DK051362, R37DK044319, R01DK051362, P30DK034854, R01DK044319, R01DK088199)
- National Institute of Neurological Disorders and Stroke (NS045937, R01NS045937)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- TIM-3, T cell exhaustion, immune tolerance, immune checkpoint, T cell co-inhibition, T cell costimulation, colorectal cancer, antitumor immunity, T cell receptor signaling
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Animals, Cell Line, Disease Models, Animal, Female, Humans, Immune Tolerance, Inflammation, Ligands, Male, Membrane Proteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Models, Molecular, Mucous Membrane, Protein Conformation, Receptors, Virus, T-Lymphocytes, Colorectal Neoplasms, Autoimmunity, Antigens, CD, Cell Adhesion Molecules, Mice, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.